Table 2 Peripheral Blood Mononuclear Cell Phenotyping of 2 patients with Goldenhar Syndrome
From: Goldenhar syndrome: a cause of secondary immunodeficiency?
MONONUCLEAR CELL PHENOTYPES | % OF TOTAL GATED POPULATION | CELL COUNTS | ||
|---|---|---|---|---|
PATIENT 1 | PATIENT 2 | PATIENT 1 | PATIENT 2 | |
3 y | 7 y | (#/mm^3) 3 y | (#/mm^3) 7 y | |
CD45+ (Purity) | 100.0 (100) | 100.0 (100) | 2483 (N/A) | 1726 (N/A) |
CD3-CD56,16+ | 12.5 (3.0–18.6) | 17 (5–21) | 311 (123–785) | 815 (128–474) |
CD56+ | 10.1 (6.2–23.2) | 17 (6–23) | 251 (137–478) | 815 (137–478) |
CD2+ | 64.6 (69.8–93.2) | 64 (70–93) | 1604 (884–2800) | 3068 (884–2800) |
CD3+ (Total) | 57.5 (58.0–74.0) | 58 (56–76) | 1427 (1656–3841) | 2781 (991–2997) |
CD3+CD4+ | 39.6 (28.0–47.2) | 33.9 (25–48) | 983 (871–2379) | 1625 (635–1620) |
CD3+CD8+ | 15.5 (16.0–31.8) | 19 (16–43) | 384 (518–1433) | 911 (293–1221) |
CD19+ | 28.7 (12.8–30.6) | 24 (11–28) | 713 (421–1397) | 1151 (249–865) |
CD20+ | 27.7 (2.7–24.9) | 23 (3–25) | 688 (59–457) | 1103 (59–457) |
CD19+CD27+ | 2.1 (1.0–5.2) | 1.9 (1–5) | 52 (19–131) | 91 (19–131) |
HLA-DR+ | 36.3 (8.9–36.4) | 29 (9–36) | 901 (177–692) | 1390 (59–457) |
CD4+CD45RA+ | 27.6 (3.3–32.9) | 24 (3–33) | 686 (134–969) | 1151 (134–969) |
CD4+CD45RO+ | 10.8 (15.6–41.8) | 10 (16–42) | 269 (301–919) | 479 (301–919) |
CD4/CD8 Ratio | 2.56 (0.72–2.94) | 1.78 (0.69–2.63) | N/A | N/A |